Selskapet har i samråd med sin revisor besluttet å foreta presiseringer i årsregnskapet. Selskapet ønsker å innarbeide en bedre beskrivelse av selskapets utvikling, og mer informative forutsetninger rundt impairmenttest. Det vil derfor bli utarbeidet nytt årsregnskap der det antas å ikke innebære endringer i årsresultat
This information is subject of the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.
Recommended Reading
-
Reference is made to the stock exchange announcement by Hofseth BioCare ASA (the "Company") from 28 June 2026 regarding the successful placing of a private placement of new Ordinary Shares in the...
Read More -
Christoph Baldegger, primary insider and member of the Board of Directors in Hofseth BioCare ASA ("HBC") has today, 17 September 2026, bought 2,500,000 shares in HBC in an off-market transaction at an...
Read More